Select Page

Press Releases

Sign up to get full access to all our latest Press Releases

Rapid Dose Therapeutics Announces Issuance of Management Cease Trade Order

June 30, 2022


BURLINGTON, Ontario – June 30, 2022: Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, announces that, further to its press release dated June 16, 2022 (the “Default Announcement”), at the request of the Company, the...

Rapid Dose Therapeutics Announces Delay in Filing Annual Financial Statements

June 16, 2022


Rapid Dose Therapeutics Announces Delay in Filing Annual Financial Statements BURLINGTON, Ontario – June 16, 2022: Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, announces that it will not be in a position to file...

Rapid Dose Therapeutics Corp Announces Proposed Private Placement

May 26, 2022


BURLINGTON, Ontario – May 26, 2022: Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, today announced that it plans to complete a private placement financing (the “Financing”) for up to $5,000,000 of gross proceeds, consisting...

Rapid Dose Therapeutics Closes First Tranche of Private Placement

May 25, 2022


BURLINGTON, Ontario – May 25, 2022: Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, is pleased to announce the closing of the first tranche of a Private Placement. The tranche consists of 506,157 Common Share...

Rapid Dose Therapeutics Provides Shareholder Update Regarding Vaccine Collaboration Agreement with Oakland Health Limited in the United Kingdom

May 12, 2022


BURLINGTON, Ontario – May 12, 2022: Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, provides the following update regarding the signing of a number of strategically significant  agreements with Oakland Health Limited (operating as “RD...

Rapid Dose Therapeutics and Skycare Compounding Labs to Provide Patients with a Novel Oral Delivery Option for Pharmaceutical Products

April 26, 2022


BURLINGTON, Ontario – April 26, 2022- Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform and Skycare Compounding Labs (“Skycare”) a leader in compounding services for the Canadian prescription market, today announce the...

RD Therapeutics and Rapid Dose Therapeutics Participate in the CEPI Global Pandemic Preparedness Summit and Support the #100DaysMission — the value of needle-free vaccination, such as the QuickStrip™, will be discussed.

March 7, 2022


BURLINGTON, Ontario – March 8, 2022- Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company focused on health and wellness leveraging an innovative, proprietary oral delivery medication and nutraceutical platform, along with their UK and European partner RD Therapeutics, proudly...

Rapid Dose Therapeutics Announces Management Change

February 10, 2022


BURLINGTON, Ontario – February 10, 2022- Rapid Dose Therapeutics Corp. (“RDT” or the“Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation today announced a management change in the Company. The Board of Directors provided notice on February 9, 2022 of its intention...

Rapid Dose Therapeutics Appoints Dr. Michael Glogauer to Advisory Board

January 5, 2022


BURLINGTON, Ontario – January 5, 2022- Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is pleased to announce another significant addition to the Company’s advisory board with the appointment of Dr. Michael Glogauer. Dr....

Rapid Dose Therapeutics and McMaster University’s COVID-19 Vaccine Study Receives NSERC Research and Development Grant

December 22, 2021


BURLINGTON, Ontario – December 22, 2021- Today, Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) and McMaster University (“McMaster”) are pleased to announce that the ongoing development of an orally delivered vaccine candidate for COVID-19 has received the final instalment of the Collaborative...

1 2 3 4 5 6 7 8 9